{"organizations": [], "uuid": "d71f973e67768960c834b452a4216bafe58fe875", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180510.html", "section_title": "Archive News &amp; Video for Thursday, 10 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sierra-oncology-reports-qtrly-loss/brief-sierra-oncology-reports-qtrly-loss-per-share-0-19-idUSASC0A1CE", "country": "US", "domain_rank": 408, "title": "BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-10T19:08:00.000+03:00", "replies_count": 0, "uuid": "d71f973e67768960c834b452a4216bafe58fe875"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sierra-oncology-reports-qtrly-loss/brief-sierra-oncology-reports-qtrly-loss-per-share-0-19-idUSASC0A1CE", "ord_in_thread": 0, "title": "BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sierra", "sentiment": "negative"}, {"name": "sierra oncology inc", "sentiment": "negative"}, {"name": "cology inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10 (Reuters) - Sierra Oncology Inc:\n* SIERRA ONCOLOGY INC QTRLY LOSS PER SHARE $0.19 * SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT\n* SIERRA ONCOLOGY INC - SRA737 LOW-DOSE GEMCITABINE COMBINATION PHASE 1/2 TRIAL ADVANCED INTO COHORT EXPANSION PHASE\n* SIERRA ONCOLOGY INC - CASH AND CASH EQUIVALENTS TOTALED $133.8 MILLION AS OF MARCH 31, 2018\n* SIERRA ONCOLOGY INC - $133.8 MILLION CASH EXPECTED TO FUND PROGRAMS THROUGH APPROXIMATELY MID-2020 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-10T19:08:00.000+03:00", "crawled": "2018-05-11T12:55:21.021+03:00", "highlightTitle": ""}